Testing effectiveness (Phase 2)Ended earlyNCT03499353
What this trial is testing
Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Who this might be right for
Early Breast Cancer
Pfizer 61